Kinematic changes following concurrent epidural injection with autologous conditioned serum (ACS) and glucocorticoids in dogs with cauda equina syndrome
4 affiliations
- 1orthoVET, Fasanenstrasse 13, Frenkendorf, CH-4402, Switzerland
- 2Cavia, Iwamoto 537132, Fuji, Shizuoka, 416-0901, Japan
- 3FHNW University of Applied Sciences Northwestern Switzerland - Campus Muttenz, Hofackerstrasse 30, 4132 Muttenz, Basel-Land, Switzerland
- 4Orthogen Veterinary GmbH, Ernst-Schneider-Platz 1, Düsseldorf, 40212, Germany
Abstract
Degenerative lumbosacral stenosis (DLSS) causes progressive nerve root compression, leading to cauda equina syndrome (CES) and painful gait impairments in dogs. Epidural co-administration of autologous conditioned serum (ACS) and glucocorticoids (GC) is used as a conservative intervention, but objective outcome data remain lacking. This retrospective exploratory study evaluated whether an inertial measurement unit (IMU)-based kinematic system (LupoGait) could detect gait changes following a single epidural injection of ACS and triamcinolone acetonide in 44 dogs with CES. Nominal post-treatment changes were observed in several hindlimb parameters, including stance phase (HL +0.03, 95% CI 0.005–0.05, p = 0.018), maximum gyroscope amplitude (HL +0.32, 95% CI 0.02 to 0.69, p = 0.032), and variance of the differentiated gyroscope signal (HL +0.10, 95% CI 0.01 to 0.23, p = 0.036). However, no evaluated outcomes remained statistically significant after correction for multiple comparisons. Given the uncontrolled retrospective design, these exploratory findings cannot establish therapeutic efficacy or isolate ACS-specific effects from GC administration. Nevertheless, this study demonstrates the feasibility of IMU-based kinematic analysis for objective longitudinal monitoring in dogs with CES and provides preliminary baseline data for prospective, controlled clinical trials.
Related
- Neural responses to conditioned threat during extinction predict concurrent and future anxiety in late adolescence
- DNA Methylation Alterations in Patients with Moderate-to-Severe Thyroid Eye Disease Treated with Intravenous Glucocorticoids
- A prefrontal–bed nucleus pathway controls aversive memory specificity independently of glucocorticoids
- Glucocorticoids impair memory inference through noradrenergic disruption of GABAergic regulation in hippocampal CA3
- Glucocorticoids in breast cancer: physiologic mechanisms and relationship to risk, survival, and treatment response.
BibTeX
@article{monnier2026kinematic,
title = {{Kinematic changes following concurrent epidural injection with autologous conditioned serum (ACS) and glucocorticoids in dogs with cauda equina syndrome}},
author = {Patrick Blaettler Monnier and Indre Matsuzaki and Nico Gruetter and Julien Troillet},
journal = {Veterinary and Animal Science},
year = {2026},
month = oct,
doi = {10.1016/j.vas.2026.100911},
url = {https://doi.org/10.1016/j.vas.2026.100911},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Kinematic changes following concurrent epidural injection with autologous conditioned serum (ACS) and glucocorticoids in dogs with cauda equina syndrome
AU - Patrick Blaettler Monnier
AU - Indre Matsuzaki
AU - Nico Gruetter
AU - Julien Troillet
PY - 2026
DA - 2026/10/20
JO - Veterinary and Animal Science
DO - 10.1016/j.vas.2026.100911
UR - https://doi.org/10.1016/j.vas.2026.100911
AB - Degenerative lumbosacral stenosis (DLSS) causes progressive nerve root compression, leading to cauda equina syndrome (CES) and painful gait impairments in dogs. Epidural co-administration of autologous conditioned serum (ACS) and glucocorticoids (GC) is used as a conservative intervention, but objective outcome data remain lacking. This retrospective exploratory study evaluated whether an inertial measurement unit (IMU)-based kinematic system (LupoGait) could detect gait changes following a single epidural injection of ACS and triamcinolone acetonide in 44 dogs with CES. Nominal post-treatment changes were observed in several hindlimb parameters, including stance phase (HL +0.03, 95% CI 0.005–0.05, p = 0.018), maximum gyroscope amplitude (HL +0.32, 95% CI 0.02 to 0.69, p = 0.032), and variance of the differentiated gyroscope signal (HL +0.10, 95% CI 0.01 to 0.23, p = 0.036). However, no evaluated outcomes remained statistically significant after correction for multiple comparisons. Given the uncontrolled retrospective design, these exploratory findings cannot establish therapeutic efficacy or isolate ACS-specific effects from GC administration. Nevertheless, this study demonstrates the feasibility of IMU-based kinematic analysis for objective longitudinal monitoring in dogs with CES and provides preliminary baseline data for prospective, controlled clinical trials.
SN - 2451-943X
ER -